GlaxoSmithKline PLC Director/PDMR Shareholding (2674F)
July 14 2021 - 9:34AM
UK Regulatory
TIDMGSK
RNS Number : 2674F
GlaxoSmithKline PLC
14 July 2021
GlaxoSmithKline plc (the ' Company ')
Transaction notification
1. Details of PDMR/person closely associated with them
('PCA')
==== ============================================================================================
a) Name Ms E Walmsley
==== ====================================== ====================================================
b) Position/status Chief Executive Officer
==== ====================================== ====================================================
c) Initial notification/ Initial notification
amendment
==== ====================================== ====================================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
==== ============================================================================================
a) Name GlaxoSmithKline plc
==== ====================================== ====================================================
b) LEI 5493000HZTVUYLO1D793
==== ====================================== ====================================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
==== ============================================================================================
a) Description of Ordinary shares of 25 pence each ('Ordinary
the financial Shares')
instrument ISIN: GB0009252882
==== ====================================== ====================================================
b) Nature of the Increase in notional interest in Ordinary
transaction Shares following the re-investment of dividends
paid to shareholders on 8 July 2021 on
Ordinary Shares held in the Company's Deferred
Annual Bonus Plan
==== ====================================== ====================================================
c) Price(s) and Price(s) Volume(s)
volume(s)
==== ====================================== ========================== ======================
GBP14.2600 927
=========================================== ========================== ======================
GBP14.2600 745
========================== ======================
GBP14.2600 620
========================== ======================
d) Aggregated information 2,292
====
Aggregated volume GBP14.2600
Price
=========================================== ====================================================
e) Date of the transaction 2021-07-12
==== ====================================== ====================================================
f) Place of the London Stock Exchange (XLON)
transaction
==== ====================================== ====================================================
1. Details of PDMR/person closely associated with them
('PCA')
==== ============================================================================================
a) Name Dr H Barron
==== ======================================= ===================================================
b) Position/status Chief Scientific Officer and President,
R&D
==== ======================================= ===================================================
c) Initial notification/ Initial notification
amendment
==== ======================================= ===================================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
==== ============================================================================================
a) Name GlaxoSmithKline plc
==== ======================================= ===================================================
b) LEI 5493000HZTVUYLO1D793
==== ======================================= ===================================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
==== ============================================================================================
a) Description of American Depositary Shares ('ADSs')
the financial ISIN: US37733W1053
instrument
==== ======================================= ===================================================
b) Nature of the Increase in notional interest in ADSs following
transaction the re-investment of dividends paid to
shareholders on 8 July 2021 on ADSs held
in the Company's Deferred Annual Bonus
Plan
==== ======================================= ===================================================
c) Price(s) and Price(s) Volume(s)
volume(s)
==== ======================================= ========================= ======================
$ 39.9700 540
============================================ ========================= ======================
$ 39.9700 424
========================= ======================
$ 39.9700 321
========================= ======================
d) Aggregated information 1,285
====
Aggregated volume $39.9700
Price
============================================ ===================================================
e) Date of the transaction 2021-07-12
==== ======================================= ===================================================
f) Place of the New York Stock Exchange (XNYS)
transaction
==== ======================================= ===================================================
1. Details of PDMR/person closely associated with them
('PCA')
==== ===========================================================================================
a) Name Mr R Connor
==== ===================================== ====================================================
b) Position/status President, Global Vaccines
==== ===================================== ====================================================
c) Initial notification/ Initial notification
amendment
==== ===================================== ====================================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
==== ===========================================================================================
a) Name GlaxoSmithKline plc
==== ===================================== ====================================================
b) LEI 5493000HZTVUYLO1D793
==== ===================================== ====================================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
==== ===========================================================================================
a) Description of Ordinary shares of 25 pence each ('Ordinary
the financial Shares')
instrument ISIN: GB0009252882
==== ===================================== ====================================================
b) Nature of the Increase in notional interest in Ordinary
transaction Shares following the re-investment of dividends
paid to shareholders on 8 July 2021 on
Ordinary Shares held in the Company's Deferred
Annual Bonus Plan
==== ===================================== ====================================================
c) Price(s) and Price(s) Volume(s)
volume(s)
==== ===================================== =========================== =====================
GBP 14.2600 243
========================================== =========================== =====================
GBP 14.2600 235
=========================== =====================
GBP 14.2600 136
=========================== =====================
d) Aggregated information 614
====
Aggregated volume GBP 14.2600
Price
========================================== ====================================================
e) Date of the transaction 2021-07-12
==== ===================================== ====================================================
f) Place of the London Stock Exchange (XLON)
transaction
==== ===================================== ====================================================
1. Details of PDMR/person closely associated with them
('PCA')
==== ===========================================================================================
a) Name Ms D Conrad
==== ===================================== ====================================================
b) Position/status SVP Human Resources
==== ===================================== ====================================================
c) Initial notification/ Initial notification
amendment
==== ===================================== ====================================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
==== ===========================================================================================
a) Name GlaxoSmithKline plc
==== ===================================== ====================================================
b) LEI 5493000HZTVUYLO1D793
==== ===================================== ====================================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
==== ===========================================================================================
a) Description of Ordinary shares of 25 pence each ('Ordinary
the financial Shares')
instrument ISIN: GB0009252882
==== ===================================== ====================================================
b) Nature of the Increase in notional interest in Ordinary
transaction Shares following the re-investment of dividends
paid to shareholders on 8 July 2021 on
Ordinary Shares held in the Company's Deferred
Annual Bonus Plan
==== ===================================== ====================================================
c) Price(s) and Price(s) Volume(s)
volume(s)
==== ===================================== =========================== =====================
GBP 14.2600 97
========================================== =========================== =====================
GBP 14.2600 90
=========================== =====================
d) Aggregated information 187
====
Aggregated volume GBP14.2600
Price
========================================== ====================================================
e) Date of the transaction 2021-07-12
==== ===================================== ====================================================
f) Place of the London Stock Exchange (XLON)
transaction
==== ===================================== ====================================================
1. Details of PDMR/person closely associated with them
('PCA')
==== ============================================================================================
a) Name Mr J Ford
==== ====================================== ====================================================
b) Position/status Senior Vice President and General Counsel
==== ====================================== ====================================================
c) Initial notification/ Initial notification
amendment
==== ====================================== ====================================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
==== ============================================================================================
a) Name GlaxoSmithKline plc
==== ====================================== ====================================================
b) LEI 5493000HZTVUYLO1D793
==== ====================================== ====================================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
==== ============================================================================================
a) Description of Ordinary shares of 25 pence each ('Ordinary
the financial Shares')
instrument ISIN: GB0009252882
==== ====================================== ====================================================
b) Nature of the Increase in notional interest in Ordinary
transaction Shares following the re-investment of dividends
paid to shareholders on 8 July 2021 on
Ordinary Shares held in the Company's Deferred
Annual Bonus Plan
==== ====================================== ====================================================
c) Price(s) and Price(s) Volume(s)
volume(s)
==== ====================================== ========================== ======================
GBP14.2600 138
=========================================== ========================== ======================
GBP14.2600 108
========================== ======================
d) Aggregated information 246
====
Aggregated volume GBP14.2600
Price
=========================================== ====================================================
e) Date of the transaction 2021-07-12
==== ====================================== ====================================================
f) Place of the London Stock Exchange (XLON)
transaction
==== ====================================== ====================================================
1. Details of PDMR/person closely associated with them
('PCA')
==== =============================================================================================
a) Name Mr J Ford
==== ======================================= ====================================================
b) Position/status Senior Vice President and General Counsel
==== ======================================= ====================================================
c) Initial notification/ Initial notification
amendment
==== ======================================= ====================================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
==== =============================================================================================
a) Name GlaxoSmithKline plc
==== ======================================= ====================================================
b) LEI 5493000HZTVUYLO1D793
==== ======================================= ====================================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
==== =============================================================================================
a) Description of American Depositary Shares ('ADSs')
the financial ISIN: US37733W1053
instrument
==== ======================================= ====================================================
b) Nature of the Increase in notional interest in ADSs following
transaction the re-investment of dividends paid to
shareholders on 8 July 2021 on ADSs held
in the Company's Deferred Annual Bonus
Plan
==== ======================================= ====================================================
c) Price(s) and Price(s) Volume(s)
volume(s)
==== ======================================= ========================= ======================
$ 39.9700 46
========================= ======================
d) Aggregated information N/A (single transaction)
====
Aggregated volume
Price
======================================== ========================================================
e) Date of the transaction 2021-07-12
==== ======================================= ====================================================
f) Place of the New York Stock Exchange (XNYS)
transaction
==== ======================================= ====================================================
1. Details of PDMR/person closely associated with them
('PCA')
==== ===========================================================================================
a) Name Mr N Hirons
==== ===================================== ====================================================
b) Position/status SVP, Global Ethics & Compliance
==== ===================================== ====================================================
c) Initial notification/ Initial notification
amendment
==== ===================================== ====================================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
==== ===========================================================================================
a) Name GlaxoSmithKline plc
==== ===================================== ====================================================
b) LEI 5493000HZTVUYLO1D793
==== ===================================== ====================================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
==== ===========================================================================================
a) Description of Ordinary shares of 25 pence each ('Ordinary
the financial Shares')
instrument ISIN: GB0009252882
==== ===================================== ====================================================
b) Nature of the Increase in notional interest in Ordinary
transaction Shares following the re-investment of dividends
paid to shareholders on 8 July 2021 on
Ordinary Shares held in the Company's Deferred
Annual Bonus Plan
==== ===================================== ====================================================
c) Price(s) and Price(s) Volume(s)
volume(s)
==== ===================================== =========================== =====================
GBP 14.2600 101
========================================== =========================== =====================
GBP 14.2600 73
=========================== =====================
GBP 14.2600 54
=========================== =====================
d) Aggregated information 228
====
Aggregated volume GBP 14.2600
Price
========================================== ====================================================
e) Date of the transaction 2021-07-12
==== ===================================== ====================================================
f) Place of the London Stock Exchange (XLON)
transaction
==== ===================================== ====================================================
1. Details of PDMR/person closely associated with them
('PCA')
==== ===========================================================================================
a) Name Ms S Jackson
==== ===================================== ====================================================
b) Position/status SVP, Global Communications & CEO Office
==== ===================================== ====================================================
c) Initial notification/ Initial notification
amendment
==== ===================================== ====================================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
==== ===========================================================================================
a) Name GlaxoSmithKline plc
==== ===================================== ====================================================
b) LEI 5493000HZTVUYLO1D793
==== ===================================== ====================================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
==== ===========================================================================================
a) Description of Ordinary shares of 25 pence each ('Ordinary
the financial Shares')
instrument ISIN: GB0009252882
==== ===================================== ====================================================
b) Nature of the Increase in notional interest in Ordinary
transaction Shares following the re-investment of dividends
paid to shareholders on 8 July 2021 on
Ordinary Shares held in the Company's Deferred
Annual Bonus Plan
==== ===================================== ====================================================
c) Price(s) and Price(s) Volume(s)
volume(s)
==== ===================================== =========================== =====================
GBP 14.2600 58
========================================== =========================== =====================
GBP 14.2600 54
=========================== =====================
d) Aggregated information 112
====
Aggregated volume GBP14.2600
Price
========================================== ====================================================
e) Date of the transaction 2021-07-12
==== ===================================== ====================================================
f) Place of the London Stock Exchange (XLON)
transaction
==== ===================================== ====================================================
1. Details of PDMR/person closely associated with them
('PCA')
==== ===========================================================================================
a) Name Mr I Mackay
==== ===================================== ====================================================
b) Position/status Chief Financial Officer
==== ===================================== ====================================================
c) Initial notification/ Initial notification
amendment
==== ===================================== ====================================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
==== ===========================================================================================
a) Name GlaxoSmithKline plc
==== ===================================== ====================================================
b) LEI 5493000HZTVUYLO1D793
==== ===================================== ====================================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
==== ===========================================================================================
a) Description of Ordinary shares of 25 pence each ('Ordinary
the financial Shares')
instrument ISIN: GB0009252882
==== ===================================== ====================================================
b) Nature of the Increase in notional interest in Ordinary
transaction Shares following the re-investment of dividends
paid to shareholders on 8 July 2021 on
Ordinary Shares held in the Company's Deferred
Annual Bonus Plan
==== ===================================== ====================================================
c) Price(s) and Price(s) Volume(s)
volume(s)
==== ===================================== =========================== =====================
GBP 14.2600 503
========================================== =========================== =====================
GBP14.2600 430
=========================== =====================
d) Aggregated information 933
====
Aggregated volume GBP14.2600
Price
========================================== ====================================================
e) Date of the transaction 2021-07-12
==== ===================================== ====================================================
f) Place of the London Stock Exchange (XLON)
transaction
==== ===================================== ====================================================
1. Details of PDMR/person closely associated with them
('PCA')
==== ============================================================================================
a) Name Mr B McNamara
==== ======================================= ===================================================
b) Position/status CEO, GSK Consumer Healthcare
==== ======================================= ===================================================
c) Initial notification/ Initial notification
amendment
==== ======================================= ===================================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
==== ============================================================================================
a) Name GlaxoSmithKline plc
==== ======================================= ===================================================
b) LEI 5493000HZTVUYLO1D793
==== ======================================= ===================================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
==== ============================================================================================
a) Description of American Depositary Shares ('ADSs')
the financial ISIN: US37733W1053
instrument
==== ======================================= ===================================================
b) Nature of the Increase in notional interest in ADSs following
transaction the re-investment of dividends paid to
shareholders on 8 July 2021 on ADSs held
in the Company's Deferred Annual Bonus
Plan
==== ======================================= ===================================================
c) Price(s) and Price(s) Volume(s)
volume(s)
==== --------------------------------------- ========================= ======================
$ 39.9700 91
-------------------------------------------- ========================= ======================
$ 39.9700 78
========================= ======================
$ 39.9700 98
------------------------- ----------------------
d) Aggregated information 267
====
Aggregated volume $ 39.9700
Price
============================================ ===================================================
e) Date of the transaction 2021-07-12
==== ======================================= ===================================================
f) Place of the New York Stock Exchange (XNYS)
transaction
==== ======================================= ===================================================
1. Details of PDMR/person closely associated with them
('PCA')
==== ============================================================================================
a) Name Mr L Miels
==== ====================================== ====================================================
b) Position/status President, Global Pharmaceuticals
==== ====================================== ====================================================
c) Initial notification/ Initial notification
amendment
==== ====================================== ====================================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
==== ============================================================================================
a) Name GlaxoSmithKline plc
==== ====================================== ====================================================
b) LEI 5493000HZTVUYLO1D793
==== ====================================== ====================================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
==== ============================================================================================
a) Description of Ordinary shares of 25 pence each ('Ordinary
the financial Shares')
instrument ISIN: GB0009252882
==== ====================================== ====================================================
b) Nature of the Increase in notional interest in Ordinary
transaction Shares following the re-investment of dividends
paid to shareholders on 8 July 2021 on
Ordinary Shares held in the Company's Deferred
Annual Bonus Plan
==== ====================================== ====================================================
c) Price(s) and Price(s) Volume(s)
volume(s)
==== ====================================== ========================== ======================
GBP14.2600 258
=========================================== ========================== ======================
GBP14.2600 225
========================== ======================
GBP14.2600 168
========================== ======================
d) Aggregated information 651
====
Aggregated volume GBP14.2600
Price
=========================================== ====================================================
e) Date of the transaction 2021-07-12
==== ====================================== ====================================================
f) Place of the London Stock Exchange (XLON)
transaction
==== ====================================== ====================================================
1. Details of PDMR/person closely associated with them
('PCA')
==== ============================================================================================
a) Name Mr D Redfern
==== ====================================== ====================================================
b) Position/status Chief Strategy Officer
==== ====================================== ====================================================
c) Initial notification/ Initial notification
amendment
==== ====================================== ====================================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
==== ============================================================================================
a) Name GlaxoSmithKline plc
==== ====================================== ====================================================
b) LEI 5493000HZTVUYLO1D793
==== ====================================== ====================================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
==== ============================================================================================
a) Description of Ordinary shares of 25 pence each ('Ordinary
the financial Shares')
instrument ISIN: GB0009252882
==== ====================================== ====================================================
b) Nature of the Increase in notional interest in Ordinary
transaction Shares following the re-investment of dividends
paid to shareholders on 8 July 2021 on
Ordinary Shares held in the Company's Deferred
Annual Bonus Plan
==== ====================================== ====================================================
c) Price(s) and Price(s) Volume(s)
volume(s)
==== ====================================== ========================== ======================
GBP14.2600 229
=========================================== ========================== ======================
GBP14.2600 165
========================== ======================
GBP14.2600 132
========================== ======================
d) Aggregated information 526
====
Aggregated volume GBP14.2600
Price
=========================================== ====================================================
e) Date of the transaction 2021-07-12
==== ====================================== ====================================================
f) Place of the London Stock Exchange (XLON)
transaction
==== ====================================== ====================================================
1. Details of PDMR/person closely associated with them
('PCA')
==== ============================================================================================
a) Name Mr R Simard
==== ====================================== ====================================================
b) Position/status President, Pharmaceuticals Supply Chain
==== ====================================== ====================================================
c) Initial notification/ Initial notification
amendment
==== ====================================== ====================================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
==== ============================================================================================
a) Name GlaxoSmithKline plc
==== ====================================== ====================================================
b) LEI 5493000HZTVUYLO1D793
==== ====================================== ====================================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
==== ============================================================================================
a) Description of Ordinary shares of 25 pence each ('Ordinary
the financial Shares')
instrument ISIN: GB0009252882
==== ====================================== ====================================================
b) Nature of the Increase in notional interest in Ordinary
transaction Shares following the re-investment of dividends
paid to shareholders on 8 July 2021 on
Ordinary Shares held in the Company's Deferred
Annual Bonus Plan
==== ====================================== ====================================================
c) Price(s) and Price(s) Volume(s)
volume(s)
==== ====================================== ========================== ======================
GBP14.2600 83
=========================================== ========================== ======================
GBP14.2600 117
========================== ======================
GBP14.2600 99
========================== ======================
d) Aggregated information 299
====
Aggregated volume GBP14.2600
Price
=========================================== ====================================================
e) Date of the transaction 2021-07-12
==== ====================================== ====================================================
f) Place of the London Stock Exchange (XLON)
transaction
==== ====================================== ====================================================
1. Details of PDMR/person closely associated with them
('PCA')
==== ============================================================================================
a) Name Ms K Terrell
==== ======================================= ===================================================
b) Position/status Chief Digital & Technology Officer
==== ======================================= ===================================================
c) Initial notification/ Initial notification
amendment
==== ======================================= ===================================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
==== ============================================================================================
a) Name GlaxoSmithKline plc
==== ======================================= ===================================================
b) LEI 5493000HZTVUYLO1D793
==== ======================================= ===================================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
==== ============================================================================================
a) Description of American Depositary Shares ('ADSs')
the financial ISIN: US37733W1053
instrument
==== ======================================= ===================================================
b) Nature of the Increase in notional interest in ADSs following
transaction the re-investment of dividends paid to
shareholders on 8 July 2021 on ADSs held
in the Company's Deferred Annual Bonus
Plan
==== ======================================= ===================================================
c) Price(s) and Price(s) Volume(s)
volume(s)
==== ======================================= ========================= ======================
$ 39.9700 115
============================================ ========================= ======================
$ 39.9700 79
========================= ======================
$ 39.9700 62
========================= ======================
d) Aggregated information 256
====
Aggregated volume $ 39.9700
Price
============================================ ===================================================
e) Date of the transaction 2021-07-12
==== ======================================= ===================================================
f) Place of the New York Stock Exchange (XNYS)
transaction
==== ======================================= ===================================================
1. Details of PDMR/person closely associated with them
('PCA')
==== ============================================================================================
a) Name Mr P Thomson
==== ====================================== ====================================================
b) Position/status President, Global Affairs
==== ====================================== ====================================================
c) Initial notification/ Initial notification
amendment
==== ====================================== ====================================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
==== ============================================================================================
a) Name GlaxoSmithKline plc
==== ====================================== ====================================================
b) LEI 5493000HZTVUYLO1D793
==== ====================================== ====================================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
==== ============================================================================================
a) Description of Ordinary shares of 25 pence each ('Ordinary
the financial Shares')
instrument ISIN: GB0009252882
==== ====================================== ====================================================
b) Nature of the Increase in notional interest in Ordinary
transaction Shares following the re-investment of dividends
paid to shareholders on 8 July 2021 on
Ordinary Shares held in the Company's Deferred
Annual Bonus Plan
==== ====================================== ====================================================
c) Price(s) and Price(s) Volume(s)
volume(s)
==== ====================================== ========================== ======================
GBP14.2600 134
=========================================== ========================== ======================
GBP14.2600 95
========================== ======================
GBP14.2600 77
========================== ======================
d) Aggregated information 306
====
Aggregated volume GBP14.2600
Price
=========================================== ====================================================
e) Date of the transaction 2021-07-12
==== ====================================== ====================================================
f) Place of the London Stock Exchange (XLON)
transaction
==== ====================================== ====================================================
1. Details of PDMR/person closely associated with them
('PCA')
==== ==============================================================================================
a) Name Ms D Waterhouse
==== ====================================== ======================================================
b) Position/status Chief Executive Officer of ViiV Healthcare
==== ====================================== ======================================================
c) Initial notification/ Initial notification
amendment
==== ====================================== ======================================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
==== ==============================================================================================
a) Name GlaxoSmithKline plc
==== ====================================== ======================================================
b) LEI 5493000HZTVUYLO1D793
==== ====================================== ======================================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
==== ==============================================================================================
a) Description of Ordinary shares of 25 pence each ('Ordinary
the financial Shares')
instrument
ISIN: GB0009252882
==== ====================================== ======================================================
b) Nature of the Increase in notional interest in Ordinary
transaction Shares following the re-investment of dividends
paid to shareholders on 8 July 2021 on
Ordinary Shares held in the Company's Deferred
Annual Bonus Plan
==== ====================================== ======================================================
c) Price(s) and Price(s) Volume(s)
volume(s)
==== ====================================== =========================== ======================
GBP14.2600 158
======================================================================= ======================
d) Aggregated information N/A (single transaction)
====
Aggregated volume
Price
==================================================================== =============================
e) Date of the transaction 2021-07-12
==== ====================================== ======================================================
f) Place of the London Stock Exchange (XLON)
transaction
==== ====================================== ======================================================
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
DSHZZLFFFDLXBBL
(END) Dow Jones Newswires
July 14, 2021 10:34 ET (14:34 GMT)
Gsk (LSE:GSK)
Historical Stock Chart
From Mar 2024 to Apr 2024
Gsk (LSE:GSK)
Historical Stock Chart
From Apr 2023 to Apr 2024
